136 related articles for article (PubMed ID: 36482562)
1. Significant role of savolitinib in a case of advanced gastric cancer with abnormal mesenchymal-epithelial transition factor (MET): A case report.
He X; An G
Medicine (Baltimore); 2022 Dec; 101(48):e32072. PubMed ID: 36482562
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and
Ye W; He L; Su L; Zheng Z; Ding M; Ye S
Front Oncol; 2022; 12():868654. PubMed ID: 35444940
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
4. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Kawakami H; Okamoto I
Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587
[TBL] [Abstract][Full Text] [Related]
5. Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report.
Yan N; Zhang Z; Guo S; Shen S; Li X
Front Med (Lausanne); 2023; 10():1130012. PubMed ID: 37293311
[TBL] [Abstract][Full Text] [Related]
6. Role of c-mesenchymal-epithelial transition pathway in gastric cancer.
Fioroni I; Dell'Aquila E; Pantano F; Intagliata S; Caricato M; Vincenzi B; Coppola R; Santini D; Tonini G
Expert Opin Pharmacother; 2015 Jun; 16(8):1195-207. PubMed ID: 25881479
[TBL] [Abstract][Full Text] [Related]
7. Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1-positive patient with advanced non-small cell lung cancer.
Xiong Y; Cao Q; Guo Y; Liu X; Zhu X; Dai B; Zhu B
Front Pharmacol; 2023; 14():1089184. PubMed ID: 36817157
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient.
Zhou S; Xu B; Qi L; Zhu D; Liu B; Wei J
Cancer Biol Ther; 2019; 20(1):15-20. PubMed ID: 30118648
[TBL] [Abstract][Full Text] [Related]
9. Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring
Han S; Fang J; Lu S; Wang L; Li J; Cheng M; Ren Y; Su W
Onco Targets Ther; 2019; 12():7323-7328. PubMed ID: 31564914
[TBL] [Abstract][Full Text] [Related]
10. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.
Kuboki Y; Yamashita S; Niwa T; Ushijima T; Nagatsuma A; Kuwata T; Yoshino T; Doi T; Ochiai A; Ohtsu A
Ann Oncol; 2016 Jan; 27(1):127-33. PubMed ID: 26489445
[TBL] [Abstract][Full Text] [Related]
12. cMET as a potential therapeutic target in gastric cancer (Review).
Teng L; Lu J
Int J Mol Med; 2013 Dec; 32(6):1247-54. PubMed ID: 24141315
[TBL] [Abstract][Full Text] [Related]
13. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
14. Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature review.
Hou GX; Song BB
Math Biosci Eng; 2019 Jun; 16(5):5923-5930. PubMed ID: 31499745
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
Du J; Wu X; Tong X; Wang X; Wei J; Yang Y; Chang Z; Mao Y; Shao YW; Liu B
Oncotarget; 2017 Apr; 8(16):26281-26287. PubMed ID: 28460431
[TBL] [Abstract][Full Text] [Related]
16. Frequent amplification of the c-met gene in scirrhous type stomach cancer.
Kuniyasu H; Yasui W; Kitadai Y; Yokozaki H; Ito H; Tahara E
Biochem Biophys Res Commun; 1992 Nov; 189(1):227-32. PubMed ID: 1333188
[TBL] [Abstract][Full Text] [Related]
17. A case report of response to crizotinib in chemotherapy-refractory metastatic gallbladder cancer with met amplification and acquired resistance resulting from the loss of MET amplification.
Sun H; Li X; Dai S; Shen X; Qiu M
Precis Clin Med; 2021 Sep; 4(3):209-214. PubMed ID: 35693217
[TBL] [Abstract][Full Text] [Related]
18. Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients.
Wang N; She J; Liu W; Shi J; Yang Q; Shi B; Hou P
Cell Cycle; 2015; 14(5):732-43. PubMed ID: 25590580
[TBL] [Abstract][Full Text] [Related]
19. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
